$162.60
-1.09-0.67%
Last update: Nov 10, 9:30 AM
Novartis AG
NVSNYSE
Novartis rose 28.7% from $127.20 to $163.69, ahead of the S&P 500's +10.5%. Its worst day was Sep 8 (−13.9%), and its low came Nov 20 at $124.36.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Novartis closed at its lowest level of the year, 2.2% below where the year started.
−2.3% · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
EPS of $2.03 beat the $2.00 estimate on $13.3B revenue (est. $13.9B).
+2.0% · S&P 500 −0.5%
Novartis closed at its highest level of the year, 32.6% above where the year started.
+1.9% · S&P 500 −0.5%
EPS of $1.99 missed the $2.07 estimate on $13.1B revenue (est. $13.5B).
+0.9% · S&P 500 −0.5%
EPS of $2.41 beat the $2.16 estimate on $14.4B revenue (est. $14.1B).
+2.9% · S&P 500 +0.8%
Novartis shares fell 13.9%, while the S&P 500 fell 0.5%.
−13.9%, the year's worst day, on 10M shares, the year's heaviest volume · S&P 500 −0.5%
EPS of $2.46 beat the $2.24 estimate on $14.5B revenue (est. $14.6B).
+2.0% · S&P 500 +0.6%
Where it ended: a close of $163.69 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 3, 2027 (EPS est. $2.23, revenue est. $14.8B).
Nothing in the past 12 months.
All NVS dividend historyAs of the Nov 9, 2026 close
Replay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NVS and SPY from Benzinga historical bars. Not investment advice.
